γδ T cells in cancer immunotherapy.
γδ T cells are one of the three immune cell types that express antigen receptors. They contribute to lymphoid antitumor surveillance and bridge the gap between innate and adaptive immunity. γδ T cells have the capacity of secreting abundant cytokines and exerting potent cytotoxicity against a wide range of cancer cells. γδ T cells exhibit important roles in immune-surveillance and immune defense against tumors and have become attractive effector cells for cancer immunotherapy. γδ T cells mediate anti-tumor therapy mainly by secreting pro-apoptotic molecules and inflammatory cytokines, or through a TCR-dependent pathway. Recently, γδ T cells are making their way into clinical trials. Some clinical trials demonstrated that γδ T cell-based immunotherapy is well tolerated and efficient. Despite the advantages that could be exploited, there are obstacles have to be addressed for the development of γδ T cell immunotherapies. Future direction for immunotherapy using γδ T cells should focus on overcoming the side effects of γδ T cells and exploring better antigens that help stimulating γδ T cell expansion in vitro.
Clinical Medical Research Center, The Second Clinical College of Jinan University, Shenzhen People's Hospital, Shenzhen, China.
Chang
C
Zou
Research Institute of Shenzhen Hornetcorn biotechnology, Shenzhen, China.
Pan
P
Zhao
Department of Pharmacology, Laboratory of Molecular Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, Sichuan, PR China.
Zhangang
Z
Xiao
Research Institute of Shenzhen Hornetcorn biotechnology, Shenzhen, China.
Xianghua
X
Han
Research Institute of Shenzhen Hornetcorn biotechnology, Shenzhen, China.
Fan
F
Fu
Department of Pharmacology, Shenzhen Key Laboratory of translational Medicine of Tumor and Cancer Research Centre, School of Medicine, Shenzhen University, Shenzhen, China.
Li
L
Fu
D000818:Animals; D049109:Cell Proliferation; D016207:Cytokines / Q000276:immunology; D003602:Cytotoxicity, Immunologic; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000379:methods*; D008213:Lymphocyte Activation; D016246:Lymphocytes, Tumor-Infiltrating / Q000276:immunology* / Q000378:metabolism / Q000473:pathology; D009369:Neoplasms / Q000276:immunology / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D010641:Phenotype; D016692:Receptors, Antigen, T-Cell, gamma-delta / Q000276:immunology* / Q000378:metabolism; D013601:T-Lymphocytes / Q000276:immunology / Q000378:metabolism / Q000637:transplantation*; D019139:Tumor Escape
D016207:Cytokines; D016692:Receptors, Antigen, T-Cell, gamma-delta
anti-tumor; cancer treatment; immunotherapy; γδ T cells